Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
Now, a new study published in the preprint server bioRxiv in August 2020 shows that under conditions resembling those in vivo, IFNs may promote efficient viral invasion instead.
Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.
Psoriasis, a chronic skin condition that causes itchy, red, scaly patches, afflicts more than 8 million Americans and 125 million people worldwide.
Small interfering RNA (siRNA) has shown tremendous potential for treating human diseases in the past decades.
In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to researchers at the University of Colorado Anschutz Medical Campus.
Xiang-Dong Fu, PhD, has never been more excited about something in his entire career. He has long studied the basic biology of RNA, a genetic cousin of DNA, and the proteins that bind it. But a single discovery has launched Fu into a completely new field: neuroscience.
A group of researchers from University of Toronto Engineering and SickKids Hospital have developed a new way to deliver molecules that target specific genes within cells.
Disarmed anthrax toxin is being tested as a way of fighting the Covid-19 virus.
In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.
In recent years, RNA molecules, with the ability to affect or turn off pathogenic genes, have become promising drug candidates in several areas.
Hinge Therapeutics is an early-stage biopharmaceutical company focused on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs.
The Alzheimer's Association and the Rainwater Charitable Foundation have joined forces again to fund drug discovery research towards finding therapies for Alzheimer's disease, frontotemporal degeneration, and other tauopathies.
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research have developed a novel therapeutic approach to cure chronic hepatitis B.
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov. 16, at the American Heart Association's Scientific Sessions 2019.
Despite advances in cancer survival, more than 90 percent of people with pancreatic cancer die within five years. Most patients with pancreatic tumors (and half of those with colorectal cancers) carry a mutation in the KRAS gene, which normally controls cell growth and death.
Treatment with two common FDA-approved gout medications have been found to cause rapid death to the parasites that cause elephantiasis.
Scientists from the University of Cambridge have developed a platform that uses nanoparticles known as metal-organic frameworks to deliver a promising anti-cancer agent to cells.
In the human body the salt content of cells and their surrounding is regulated by sophisticated transport systems.
Physicians have long suspected that red blood cell transfusions given to premature infants with anemia may put them in danger of developing necrotizing enterocolitis, or NEC, a potentially lethal inflammatory disease of the intestines.
You could call this a neat discovery. Researchers at the University of Alabama at Birmingham have found that a tissue-specific, non-coding RNA called NEAT1 has a major, previously undescribed role in memory formation.